Metabolic syndrome increases mortality in heart failure

Clinical Cardiology

Volumn 32, Issue 6, 2009, Pages 327-331

  Tamariz, Leonardo ^a,b,c   Hassan, Benjamin ^a   Palacio, Ana ^a,b,c   Arcement, Lee ^d   Horswell, Ron ^e   Hebert, Kathy ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Leonard J Chabert Medical Center   (United States)

^e PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; DEMOGRAPHY; DRUG DOSE TITRATION; EDUCATION PROGRAM; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOCRIT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; PREVALENCE; UNITED STATES;

ADULT; AGED; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; LOUISIANA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 67650466386     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20496     Document Type: Article

References (28)

1. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28:1769-1778. (Pubitemid 40923091)
2. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49:403-414. (Pubitemid 46135879)
3. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28:2745-2749. (Pubitemid 43951170)
4. Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164:1066-1076. (Pubitemid 38668985)
5. Lorenzo C, Williams K, Gonzalez-Villalpando C, Haffner SM. The prevalence of the metabolic syndrome did not increase in Mexico City between 1990-1992 and 1997-1999 despite more central obesity. Diabetes Care. 2005;28:2480-2485.
6. Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev. 2000;5:167-173.
7. Ingelsson E, Arnlov J, Lind L, Sundstrom JMc. Metabolic syndrome and risk for heart failure in middle-aged men. Heart. 2006;92:1409-1413. (Pubitemid 44578829)
8. Wong CY, O'Moore-Sullivan T, Fang ZY, et al. Myocardial and vascular dysfunction and exercise capacity in the metabolic syndrome. Am J Cardiol. 2005;96:1686-1691. (Pubitemid 41790392)
9. Azevedo A, Bettencourt P, Almeida PB, et al. Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities - cross-sectional study of the general population. BMC Cardiovasc Disord. 2007;7:17. (Pubitemid 47018656)
10. Burchfiel CM, Skelton TN, Andrew ME, et al. Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2005;112:819-827. (Pubitemid 41170067)
11. Echahidi N, Pibarot P, Despres JP, et al. Metabolic syndrome increases operative mortality in patients undergoing coronary artery bypass grafting surgery. J Am Coll Cardiol. 2007;50:843-851. (Pubitemid 47268739)
12. Feinberg MS, Schwartz R, Tanne D, et al. Impact of the metabolic syndrome on the clinical outcomes of non-clinically diagnosed diabetic patients with acute coronary syndrome. Am J Cardiol. 2007;99:667-672. (Pubitemid 46298543)
13. Levantesi G, Macchia A, Marfisi R, et al. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol. 2005;46:277-283. (Pubitemid 40966856)
14. Zeller M, Steg PG, Ravisy J, et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med. 2005; 165:1192-1198. (Pubitemid 40720745)
15. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497. (Pubitemid 32433843)
16. Pyorala K, Ballantyne CM, Gumbiner B, et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 2004;27:1735-1740. (Pubitemid 38857452)
17. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 2004;93:136-141. (Pubitemid 38058719)
18. He Y, Jiang B, Wang J, et al. Prevalence of the metabolic syndrome and its relation to cardiovascular disease in an elderly Chinese population. J Am Coll Cardiol. 2006;47:1588-1594.
19. Otiniano ME, Du XL, Maldonado MR, Ray L, Markides K. Effect of metabolic syndrome on heart attack and mortality in Mexican-American elderly persons: findings of 7-year follow-up from the Hispanic established population for the epidemiological study of the elderly. J Gerontol A Biol Sci Med Sci. 2005;60:466-470. (Pubitemid 40712863)
20. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245-1250. (Pubitemid 39202340)
21. de Simone G, Devereux RB, Chinali M, et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: The Strong Heart Study. Diabetes Care. 2007;30:1851-1856. (Pubitemid 47036363)
22. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716. (Pubitemid 35403784)
23. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729. (Pubitemid 20367975)
24. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation. 1995;92:3206-3211.
25. Hasking GJ, Esler MD, Jennings GL, et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73 615-621. (Pubitemid 16081418)
26. Grassi G, Dell'Oro R, Quarti-Trevano F, et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia. 2005;48:1359-1365. (Pubitemid 41186102)
27. Huggett RJ, Burns J, Mackintosh AF, Mary DA. Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension. 2004;44:847-852. (Pubitemid 39577410)
28. Grassi G, Seravalle G, Quarti-Trevano F, Scopelliti F, Dell'Oro R, et al. Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: Characteristics and mechanisms. Hypertension. 2007;49:535-541. (Pubitemid 46263238)